ANIP
NASDAQANI Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks68-30%
2026-03-012026-08-23
Mix2590d
- Insider14(56%)
- SEC Filings5(20%)
- Other2(8%)
- Earnings2(8%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. "We are excited to add Henry to our Board of Directors during this pivotal moment for the Company," stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. "His proven track record in corporate strategy and value-creating acquisitions
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $37,740 worth of shares (500 units at $75.48) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 74,424 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, GENERICS Gutwerg Ori sold $243,474 worth of shares (3,162 units at $77.00), decreasing direct ownership by 4% to 75,534 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECSEC Form 10-Q filed by ANI Pharmaceuticals Inc.10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Reports Record Second Quarter 2026 Financial ResultsQuarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-yearDiluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced financial re
- INSIDERSVP & CFO Carey Stephen P. sold $231,876 worth of shares (2,850 units at $81.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,693 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETPRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click here. Links to access the webcast and conference call will also be available on the "Events & Presentations" page of the Company’s website at https://www.anipharmaceuticals.com, under
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith covered exercise/tax liability with 2,466 shares, decreasing direct ownership by 3% to 74,924 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECSEC Form S-8 filed by ANI Pharmaceuticals Inc.S-8 - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on ANI Pharma with a new price targetCanaccord Genuity initiated coverage of ANI Pharma with a rating of Hold and set a new price target of $91.00
- PRANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology MatterTrial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement between the parties. "ANI respe
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $40,920 worth of shares (500 units at $81.84) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,390 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitisTrial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mgStudy evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists.Full results to be presented at an upcoming medical meeting PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluoci
- SECSEC Form 144 filed by ANI Pharmaceuticals Inc.144 - ANI PHARMACEUTICALS INC (0001023024) (Subject)
- INSIDERSVP & CFO Carey Stephen P. exercised 3,313 shares at a strike of $49.51 and sold $284,918 worth of shares (3,313 units at $86.00) as part of a pre-agreed trading plan (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP & CFO Carey Stephen P. sold $239,742 worth of shares (2,850 units at $84.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 177,543 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Tannenbaum Renee P was granted 4,357 shares, increasing direct ownership by 17% to 29,514 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Pera Antonio R was granted 4,357 shares, increasing direct ownership by 19% to 27,017 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Leonard Matthew J was granted 4,357 shares, increasing direct ownership by 63% to 11,221 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Haughey Thomas was granted 4,357 shares and sold $161,760 worth of shares (2,000 units at $80.88) as part of a pre-agreed trading plan, increasing direct ownership by 6% to 38,878 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $264,960 worth of shares (3,312 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
ANIP FAQ
6 questionsWhat does ANI Pharmaceuticals Inc. do?
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group...Where does ANIP stock trade?
ANI Pharmaceuticals Inc. (ANIP) is listed on NASDAQ.What sector and industry is ANIP in?
ANI Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ANIP?
ANI Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Hold on 2026-07-17.What companies are similar to ANIP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANIP side-by-side with any of them on Quantisnow.How can I track ANIP on Quantisnow?
Quantisnow aggregates ANI Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANIP to receive live email and push alerts on every new disclosure.